Early results suggest that the COVID-19 vaccine developed by BioNTech and Pfizer is more than 90 percent effective. If it also proves safe and regulators approve it soon, it could save many lives, allow people to resume a normal life, and give struggling economies a shot in the arm. It is hard to think of any other invention that could provide such a huge immediate boost—and the world has Turkish immigrants to Germany to thank for it.
Ugur Sahin, the co-founder and chief executive of BioNTech, a German biotech start-up, arrived in Germany as a child. He is the son of an auto worker who came to Germany as part of its postwar guest worker program. BioNTech’s chief medical officer, Ozlem Tureci, who is Sahin’s wife, is the daughter of a Turkish doctor who also moved to Germany. Both went on to become scientists. Their start-up, which had previously focused on developing innovative cancer treatments, is now set to be the first to use the novel messenger RNA technology to develop a vaccine. Moreover, Moderna, the U.S. biotech company whose vaccine also looks promising, was co-founded by a group that includes two immigrants—Canadian biologist Derrick Rossi and Lebanese-born scientist and investor Noubar Afeyan—and its CEO is French.
